Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/
https://www.ncbi.nlm.nih.gov/pubmed/9649142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/
https://www.ncbi.nlm.nih.gov/pubmed/9649142

Ejemplares similares